Everything about Illumina 5 base

DNA methylation sequencing can reveal regulatory information that ordinary DNA sequencing does not capture. Illumina’s 5-Base solution combines sequence and methylation information in one assay, but it is not automatically the right method for every biological question. The key is to understand which DNA modification it measures, how its conversion chemistry works, and what alternatives offer.

What is DNA methylation?

DNA methylation is a chemical modification of DNA that does not change its underlying A, C, G, and T sequence. In mammals, the best-known form is 5-methylcytosine (5mC), in which a methyl group is added to the fifth carbon of cytosine. 5mC is found most often at cytosines followed by guanine, called CpG sites, although methylation can also occur in other sequence contexts.

Methylation patterns vary among cell types and can change during development, aging, and disease. They are involved in processes such as gene regulation, genomic imprinting, and the control of repetitive DNA. Their effects depend on genomic location and cellular context: methylation is often associated with reduced transcription at gene promoters, but it is not a universal on/off switch for genes.

5-hydroxymethylcytosine (5hmC) is a related but distinct DNA modification. It can be produced from 5mC through oxidation and has its own biological significance. Methods that report a single combined methylation signal may not distinguish 5mC from 5hmC, so it is important to check which modification an assay actually measures.

Why is DNA methylation important?

Methylation helps cells maintain different patterns of gene activity while sharing essentially the same genome. Studying those patterns can help researchers investigate cell identity, development, gene regulation, and changes associated with conditions such as cancer. In cancer research, for example, methylation profiles may complement genetic variant and gene-expression data; they do not, by themselves, establish a diagnosis or explain the cause of a disease.

Methylation is also useful as a biomarker because patterns can reflect a tissue’s state or history. Interpretation still depends on sample composition, experimental design, and the genomic regions measured. A bulk sample containing several cell types can show an average that differs from the methylation state of any one cell type.

How can high-throughput sequencing study DNA methylation?

Sequencing assays generally need a way to distinguish modified cytosines from unmodified cytosines. The method used for that distinction affects DNA quality, read alignment, genomic coverage, and whether different cytosine modifications can be told apart.

Bisulfite sequencing treats DNA so that most unmodified cytosines are read as thymines after conversion and sequencing, while 5mC is generally read as cytosine. Whole-genome bisulfite sequencing (WGBS) can survey methylation across the genome at single-base resolution. Reduced-representation bisulfite sequencing (RRBS) focuses on a subset of the genome, often CpG-rich regions, to reduce sequencing requirements. Bisulfite treatment can damage or fragment DNA and reduces sequence complexity, which can make reads harder to align. Standard bisulfite sequencing also generally reads 5mC and 5hmC together as protected cytosines.

Enzymatic conversion assays use enzymes rather than bisulfite chemicals to distinguish methylated from unmethylated bases. Their exact conversion reactions and ability to detect 5mC versus 5hmC vary, so compare the assay chemistry and analysis pipeline rather than assuming all enzymatic methods provide the same measurements.

Targeted sequencing can focus on selected genes or regions when a research question is narrow and high coverage is more useful than genome-wide breadth. Arrays are another option when the goal is to measure a predefined set of CpG sites. Long-read sequencing can preserve longer-range genomic context and some platforms can call modified bases directly, but performance, coverage, and validated modification types depend on the platform and analysis workflow.

The choice between whole-genome and targeted sequencing is a question of scope: whole-genome approaches survey broadly, while enrichment or targeted approaches concentrate reads on regions chosen in advance. Illumina notes that both WGS and targeted enrichment versions of its 5-Base solution can detect methylation at single-base resolution.

Why choose Illumina 5-Base?

Illumina describes 5-Base as a DNA sequencing assay that reads the four canonical bases along with 5mC information. Its proprietary enzymatic conversion selectively converts 5mC to thymine. This is the reverse of the usual bisulfite description, in which unmodified cytosine is converted. By avoiding conversion of the more abundant unmodified cytosines, the method is designed to retain greater library complexity than bisulfite-treated libraries (WGBS-seq) and EM-seq.

The practical appeal is combining genetic and epigenetic information in one sequencing assay, rather than running separate assays for sequence variants and methylation. Illumina also describes the conversion as less damaging to DNA than chemical bisulfite treatment. These are vendor-reported assay characteristics; actual performance and cost depend on the sample, coverage, workflow, and analysis requirements. See Illumina’s FAQ for the 5-Base WGS and Enrichment kits for the kit-specific details.

There is an important limitation: the FAQ says the conversion enzyme is specific to 5mC and has minimal activity on 5hmC. The assay is therefore not designed to provide a separate 5hmC measurement. It is also designed for DNA, not methylated RNA. If distinguishing 5mC from 5hmC is central to the study, choose a method specifically validated for that distinction.

What are the alternatives to Illumina 5-Base?

There is no single best alternative; the choice depends on the modification of interest, genome coverage, sample quality, and budget.

• WGBS is a widely used genome-wide, single-base approach, but bisulfite conversion can damage DNA and reduce library complexity. Standard WGBS does not by itself separate 5mC from 5hmC.
• RRBS or targeted methylation sequencing can reduce sequencing needs when the study focuses on CpG-rich regions or a defined panel, but they do not provide the same breadth as whole-genome coverage.
• Enzymatic methylation sequencing avoids bisulfite chemicals, but the particular conversion chemistry determines what is measured. Check whether the assay distinguishes 5mC and 5hmC and whether it supports the desired variant calls.
• Methylation arrays are often useful for cost-effective profiling of established CpG sites, but they measure only the sites represented on the array.
• Native long-read sequencing can provide long-range context and may detect modified bases without a conversion step. Check platform-specific accuracy, coverage, and validation for the modification and sample type in question.

Before selecting a method, ask: Do I need genome-wide coverage or a targeted panel? Do I need 5mC only, or separate 5mC and 5hmC measurements? Must the same experiment call sequence variants? How much DNA is available, and what coverage can the budget support? Answering those questions is more useful than choosing a technology based on its name alone.